Company Growth: Thriving on Change

Following a very popular and successful first event, this is the second event of ourinaugural Innovation Series that is comprised of panel discussions with biotech and technology industry’s most successful entrepreneurs and innovators on how they have created, nurtured, and inspired “Innovation Throughout the Company’s Life Cycle.” Panelists will discuss their first-hand experience in developing employee careers and advancing more talented women into senior positions. 

Hear from CEOs who have successfully grown and evolved their companies. These leaders and entrepreneurs will discuss their leadership styles, company growing pains, changing personal and organizational skills as well as managing setbacks and driving innovation.

Come to network with other movers and shakers in the science and technology community and be inspired while enjoying appetizers, wine, and dessert



Deborah Dunsire, Chief Executive Officer, Forum Pharmaceutics

Tillman Gerngross, Chief Executive Officer, Adimab

David Schenkein, Chief Executive Officer, Agios


Download the event flyer

Download the series flyer

Download sponsorship information


Deborah Dunsire, President and CEO, Forum Pharmaceuticals

Dr. Dunsire is an industry leader who brings more than 25 years of scientific, clinical, operational, and commercial experience, and proven leadership in the biotechnology and pharmaceutical industries. Prior to joining FORUM Pharmaceuticals in 2013, she served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement, increasing the commercial mind-set across the organization, and crafting highly effective partnerships to drive the company’s growth. Millennium was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion, one of the largest biotech acquisitions at that time. Deborah was the first woman appointed to the board of Takeda Pharmaceuticals Limited in Japan. Prior to this, Deborah led the Novartis Oncology Business in North America, playing a critical role in the broad development and successful launch of a number of products, increasing revenues from $50 million to more than $2.2 billion. Deborah received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.

Tillman Gerngross, Co-Founder and CEO, Adimab

Dr. Gerngross is the co-founder and CEO of Adimab and a venture partner at SV Life Sciences. He is also the co-founder of Kreogene, an oncology drug development company. Previously, he was a co-founder of GlycoFi, Inc. (SVLSF III) and served as the company's Chief Scientific Officer until its acquisition by Merck and Co in June of 2006. In addition, Dr. Gerngross holds faculty positions at the Engineering School at Dartmouth College, as well as the Departments of Biology and Chemistry. Dr. Gerngross has a M.S. degree in Chemical Engineering and a Ph.D. in Molecular Biology from the Technical University of Vienna. From 1989-93 he was a visiting scientist and later Postdoctoral Fellow at MIT.

David Schenkein, CEO, Agios

Dr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, Dr. Schenkein was the senior vice president, clinical hematology/oncology, at Genentech, Inc., where he was responsible for leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, overseeing the clinical development of Velcade, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein spent 17 years in academic and clinical medicine as an attending physician in hematology oncology at Tufts Medical Center in Boston, where he was an associate professor and held the position of director of the Cancer Center. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.


Date and Time:

February 19, 2015
6:00 - 9:00 PM

Evening’s Schedule

6:00-7:00  Registration, Networking, Appetizers, and Wine

7:00-7:15  Welcome and Acknowledgement of Sponsors

7:15-8:30  Panel Discussion 

8:30-9:00  Optional Networking


The Broad Institute of MIT and Harvard, 415 Main StreetCambridge, MA 02142

Map and Parking Info

We appreciate The Broad Institute donating the use of their event space. 


Members: $55, Non-members: $75
Membership package: $140 for admission and an annual membership

$700 for 10 tickets, $1,000 for 15 tickets and $1,300 for 20 tickets

Cancellation Policy:
All programs are non-refundable.


To Register

This event is part of our 2014-2015 series titled “Innovation Across the Company’s Life Cycle.” The next event in series will be May 12th - The New CEO: Always Learning and Setting the Tone for Innovation on Day One.


Thank you to our Sponsors for this event!


Gold Sponsor


Silver Sponsor



Bronze Sponsor



Become a sponsor and contribute to a great cause.  For more information, email [email protected], or call 617-682-3703.   


If you are a student looking for financial assistance to attend this event, please visit